Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

Naru Zhang, Rudragouda Channappanavar, Cuiqing Ma, Lili Wang, Jian Tang, Tania Garron, Xinrong Tao, Sumaiya Tasneem, Lu Lu, Chien-Te Tseng, Yusen Zhou, Stanley Perlman, Shibo Jiang, Lanying Du

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Middle East respiratory syndrome (MERS), an emerging infectious disease caused by MERS coronavirus (MERS-CoV), has garnered worldwide attention as a consequence of its continuous spread and pandemic potential, making the development of effective vaccines a high priority. We previously demonstrated that residues 377-588 of MERS-CoV spike (S) protein receptor-binding domain (RBD) is a very promising MERS subunit vaccine candidate, capable of inducing potent neutralization antibody responses. In this study, we sought to identify an adjuvant that optimally enhanced the immunogenicity of S377-588 protein fused with Fc of human IgG (S377-588-Fc). Specifically, we compared several commercially available adjuvants, including Freund's adjuvant, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59 with regard to their capacity to enhance the immunogenicity of this subunit vaccine. In the absence of adjuvant, S377-588-Fc alone induced readily detectable neutralizing antibody and T-cell responses in immunized mice. However, incorporating an adjuvant improved its immunogenicity. Particularly, among the aforementioned adjuvants evaluated, MF59 is the most potent as judged by its superior ability to induce the highest titers of IgG, IgG1 and IgG2a subtypes, and neutralizing antibodies. The addition of MF59 significantly augmented the immunogenicity of S377-588-Fc to induce strong IgG and neutralizing antibody responses as well as protection against MERS-CoV infection in mice, suggesting that MF59 is an optimal adjuvant for MERS-CoV RBD-based subunit vaccines.

Original languageEnglish (US)
Pages (from-to)180-190
Number of pages11
JournalCellular and Molecular Immunology
Volume13
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Coronavirus Infections
Subunit Vaccines
Immunoglobulin G
Neutralizing Antibodies
Antibody Formation
Emerging Communicable Diseases
Proteins
Freund's Adjuvant
Pandemics
Aluminum
Protein Binding
Middle East Respiratory Syndrome Coronavirus
Vaccines
T-Lymphocytes
MF59 oil emulsion
Infection

Keywords

  • adjuvant effects
  • MERS
  • MERS-CoV
  • receptor-binding domain
  • subunit vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology

Cite this

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. / Zhang, Naru; Channappanavar, Rudragouda; Ma, Cuiqing; Wang, Lili; Tang, Jian; Garron, Tania; Tao, Xinrong; Tasneem, Sumaiya; Lu, Lu; Tseng, Chien-Te; Zhou, Yusen; Perlman, Stanley; Jiang, Shibo; Du, Lanying.

In: Cellular and Molecular Immunology, Vol. 13, No. 2, 01.03.2016, p. 180-190.

Research output: Contribution to journalArticle

Zhang, N, Channappanavar, R, Ma, C, Wang, L, Tang, J, Garron, T, Tao, X, Tasneem, S, Lu, L, Tseng, C-T, Zhou, Y, Perlman, S, Jiang, S & Du, L 2016, 'Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus', Cellular and Molecular Immunology, vol. 13, no. 2, pp. 180-190. https://doi.org/10.1038/cmi.2015.03
Zhang, Naru ; Channappanavar, Rudragouda ; Ma, Cuiqing ; Wang, Lili ; Tang, Jian ; Garron, Tania ; Tao, Xinrong ; Tasneem, Sumaiya ; Lu, Lu ; Tseng, Chien-Te ; Zhou, Yusen ; Perlman, Stanley ; Jiang, Shibo ; Du, Lanying. / Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. In: Cellular and Molecular Immunology. 2016 ; Vol. 13, No. 2. pp. 180-190.
@article{bd9dc09fde104628a9f70180a8eaf16e,
title = "Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus",
abstract = "Middle East respiratory syndrome (MERS), an emerging infectious disease caused by MERS coronavirus (MERS-CoV), has garnered worldwide attention as a consequence of its continuous spread and pandemic potential, making the development of effective vaccines a high priority. We previously demonstrated that residues 377-588 of MERS-CoV spike (S) protein receptor-binding domain (RBD) is a very promising MERS subunit vaccine candidate, capable of inducing potent neutralization antibody responses. In this study, we sought to identify an adjuvant that optimally enhanced the immunogenicity of S377-588 protein fused with Fc of human IgG (S377-588-Fc). Specifically, we compared several commercially available adjuvants, including Freund's adjuvant, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59 with regard to their capacity to enhance the immunogenicity of this subunit vaccine. In the absence of adjuvant, S377-588-Fc alone induced readily detectable neutralizing antibody and T-cell responses in immunized mice. However, incorporating an adjuvant improved its immunogenicity. Particularly, among the aforementioned adjuvants evaluated, MF59 is the most potent as judged by its superior ability to induce the highest titers of IgG, IgG1 and IgG2a subtypes, and neutralizing antibodies. The addition of MF59 significantly augmented the immunogenicity of S377-588-Fc to induce strong IgG and neutralizing antibody responses as well as protection against MERS-CoV infection in mice, suggesting that MF59 is an optimal adjuvant for MERS-CoV RBD-based subunit vaccines.",
keywords = "adjuvant effects, MERS, MERS-CoV, receptor-binding domain, subunit vaccine",
author = "Naru Zhang and Rudragouda Channappanavar and Cuiqing Ma and Lili Wang and Jian Tang and Tania Garron and Xinrong Tao and Sumaiya Tasneem and Lu Lu and Chien-Te Tseng and Yusen Zhou and Stanley Perlman and Shibo Jiang and Lanying Du",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/cmi.2015.03",
language = "English (US)",
volume = "13",
pages = "180--190",
journal = "Cellular and Molecular Immunology",
issn = "1672-7681",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

AU - Zhang, Naru

AU - Channappanavar, Rudragouda

AU - Ma, Cuiqing

AU - Wang, Lili

AU - Tang, Jian

AU - Garron, Tania

AU - Tao, Xinrong

AU - Tasneem, Sumaiya

AU - Lu, Lu

AU - Tseng, Chien-Te

AU - Zhou, Yusen

AU - Perlman, Stanley

AU - Jiang, Shibo

AU - Du, Lanying

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Middle East respiratory syndrome (MERS), an emerging infectious disease caused by MERS coronavirus (MERS-CoV), has garnered worldwide attention as a consequence of its continuous spread and pandemic potential, making the development of effective vaccines a high priority. We previously demonstrated that residues 377-588 of MERS-CoV spike (S) protein receptor-binding domain (RBD) is a very promising MERS subunit vaccine candidate, capable of inducing potent neutralization antibody responses. In this study, we sought to identify an adjuvant that optimally enhanced the immunogenicity of S377-588 protein fused with Fc of human IgG (S377-588-Fc). Specifically, we compared several commercially available adjuvants, including Freund's adjuvant, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59 with regard to their capacity to enhance the immunogenicity of this subunit vaccine. In the absence of adjuvant, S377-588-Fc alone induced readily detectable neutralizing antibody and T-cell responses in immunized mice. However, incorporating an adjuvant improved its immunogenicity. Particularly, among the aforementioned adjuvants evaluated, MF59 is the most potent as judged by its superior ability to induce the highest titers of IgG, IgG1 and IgG2a subtypes, and neutralizing antibodies. The addition of MF59 significantly augmented the immunogenicity of S377-588-Fc to induce strong IgG and neutralizing antibody responses as well as protection against MERS-CoV infection in mice, suggesting that MF59 is an optimal adjuvant for MERS-CoV RBD-based subunit vaccines.

AB - Middle East respiratory syndrome (MERS), an emerging infectious disease caused by MERS coronavirus (MERS-CoV), has garnered worldwide attention as a consequence of its continuous spread and pandemic potential, making the development of effective vaccines a high priority. We previously demonstrated that residues 377-588 of MERS-CoV spike (S) protein receptor-binding domain (RBD) is a very promising MERS subunit vaccine candidate, capable of inducing potent neutralization antibody responses. In this study, we sought to identify an adjuvant that optimally enhanced the immunogenicity of S377-588 protein fused with Fc of human IgG (S377-588-Fc). Specifically, we compared several commercially available adjuvants, including Freund's adjuvant, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59 with regard to their capacity to enhance the immunogenicity of this subunit vaccine. In the absence of adjuvant, S377-588-Fc alone induced readily detectable neutralizing antibody and T-cell responses in immunized mice. However, incorporating an adjuvant improved its immunogenicity. Particularly, among the aforementioned adjuvants evaluated, MF59 is the most potent as judged by its superior ability to induce the highest titers of IgG, IgG1 and IgG2a subtypes, and neutralizing antibodies. The addition of MF59 significantly augmented the immunogenicity of S377-588-Fc to induce strong IgG and neutralizing antibody responses as well as protection against MERS-CoV infection in mice, suggesting that MF59 is an optimal adjuvant for MERS-CoV RBD-based subunit vaccines.

KW - adjuvant effects

KW - MERS

KW - MERS-CoV

KW - receptor-binding domain

KW - subunit vaccine

UR - http://www.scopus.com/inward/record.url?scp=84959905145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959905145&partnerID=8YFLogxK

U2 - 10.1038/cmi.2015.03

DO - 10.1038/cmi.2015.03

M3 - Article

VL - 13

SP - 180

EP - 190

JO - Cellular and Molecular Immunology

JF - Cellular and Molecular Immunology

SN - 1672-7681

IS - 2

ER -